09.05.24
Cellares, an Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announced today the successful completion of its first cGMP Cell Shuttle at itsIDMO Smart Factory in Bridgewater, New Jersey. This significant milestone marks a key step towards the facility’s full operational capacity, which will enable the production of up to 40,000 standard CAR-T cell therapy doses per year.
The Bridgewater facility, a state-of-the-art manufacturing hub, incorporates advanced automation technologies such as the Cell Shuttle and Cell Q. These systems streamline the cell therapy manufacturing process and automate quality control measures, ensuring consistent and efficient production. The facility's interconnected software systems further enhance efficiency by automating electronic batch record generation, reducing the potential for human error.
Cellares' partners will benefit from the unprecedented scale, cost-effectiveness, and speed offered by this facility while maintaining the highest standards of quality and safety. The company plans to expand its network of IDMO Smart Factories both domestically and internationally to meet the growing global demand for cell therapies.
Cellares' CEO, Fabian Gerlinghaus, expressed his enthusiasm for this milestone, stating, "Bringing our first cGMP Cell Shuttle online in New Jersey is a major step for Cellares and our partners. This facility showcases our innovative approach and aligns with our mission to provide life-saving cell therapies to patients in need, faster and more efficiently than ever."
The Bridgewater facility, a state-of-the-art manufacturing hub, incorporates advanced automation technologies such as the Cell Shuttle and Cell Q. These systems streamline the cell therapy manufacturing process and automate quality control measures, ensuring consistent and efficient production. The facility's interconnected software systems further enhance efficiency by automating electronic batch record generation, reducing the potential for human error.
Cellares' partners will benefit from the unprecedented scale, cost-effectiveness, and speed offered by this facility while maintaining the highest standards of quality and safety. The company plans to expand its network of IDMO Smart Factories both domestically and internationally to meet the growing global demand for cell therapies.
Cellares' CEO, Fabian Gerlinghaus, expressed his enthusiasm for this milestone, stating, "Bringing our first cGMP Cell Shuttle online in New Jersey is a major step for Cellares and our partners. This facility showcases our innovative approach and aligns with our mission to provide life-saving cell therapies to patients in need, faster and more efficiently than ever."
